{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:40:09Z","timestamp":1729226409570,"version":"3.27.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,17]]},"DOI":"10.7759\/cureus.71742","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:07:58Z","timestamp":1729224478000},"source":"Crossref","is-referenced-by-count":0,"title":["Elevated Creatine Kinase (CK) and Myositis Triggered by Immune Checkpoint Inhibitors: Muscle Mysteries Unveiled"],"prefix":"10.7759","author":[{"given":"Shivani K","family":"Modi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Subedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel M","year":"2019","unstructured":"Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Reports Immunol. 2019, 2019:10.1155\/2019\/2539493","journal-title":"Case Reports Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1941874418778957","article-title":"Miller Fisher syndrome associated with immunotherapy for metastatic melanoma","volume":"8","author":"Baird-Gunning JJ","year":"2018","unstructured":"Baird-Gunning JJ, Weerasinghe D, Silsby M, Gawarikar Y, Carlino MS, Smith JL, Vucic S. Miller Fisher syndrome associated with immunotherapy for metastatic melanoma. Neurohospitalist. 2018, 8:191-3. 10.1177\/1941874418778957","journal-title":"Neurohospitalist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and Sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli LC","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, et al.. Inflammatory arthritis and Sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017, 76:43-50. 10.1136\/annrheumdis-2016-209595","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson DB","year":"2018","unstructured":"Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018, 320:1702-3. 10.1001\/jama.2018.13995","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino M","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016, 2:1607-16. 10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.10.005","article-title":"The clinical development of vaccines for HER2+ breast cancer: current landscape and future perspectives","volume":"61","author":"Costa RL","year":"2017","unstructured":"Costa RL, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2+ breast cancer: current landscape and future perspectives. Cancer Treat Rev. 2017, 61:107-15. 10.1016\/j.ctrv.2017.10.005","journal-title":"Cancer Treat Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001298","article-title":"Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis","volume":"43","author":"Larsen BT","year":"2019","unstructured":"Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC. Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol. 2019, 43:1331-40. 10.1097\/PAS.0000000000001298","journal-title":"Am J Surg Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2024-0052-OA","article-title":"Global study on the accuracy of human epidermal growth factor receptor 2 - low diagnosis in breast cancer","author":"R\u00fcschoff J","year":"2024","unstructured":"R\u00fcschoff J, Penner A, Elli IO, et al.. Global study on the accuracy of human epidermal growth factor receptor 2 - low diagnosis in breast cancer. Arch Pathol Lab Med. 2024, 10.5858\/arpa.2024-0052-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo P","year":"2022","unstructured":"Iranzo P, Callejo A, Assaf JD, et al.. Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer. Front Med (Lausanne). 2022, 9:10.3389\/fmed.2022.875974","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092687","article-title":"Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic T cell accumulation in tumours: mechanisms and therapeutic opportunities","volume":"12","author":"Freeman P","year":"2020","unstructured":"Freeman P, Mielgo A. Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic T cell accumulation in tumours: mechanisms and therapeutic opportunities. Cancers (Basel). 2020, 12:10.3390\/cancers12092687","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between Ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy","volume":"22","author":"Skarzynski M","year":"2016","unstructured":"Skarzynski M, Niemann CU, Lee YS, et al.. Interactions between Ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res. 2016, 22:86-95. 10.1158\/1078-0432.CCR-15-1304","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000455","article-title":"The University of Florida Department of Radiation Oncology guidelines for treatment of differentiated thyroid cancer with I-131 or external-beam radiotherapy","volume":"42","author":"Amdur RJ","year":"2019","unstructured":"Amdur RJ, Dagan R. The University of Florida Department of Radiation Oncology guidelines for treatment of differentiated thyroid cancer with I-131 or external-beam radiotherapy. Am J Clin Oncol. 2019, 42:92-8. 10.1097\/COC.0000000000000455","journal-title":"Am J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi HA","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, et al.. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018, 379:722-30. 10.1056\/NEJMoa1805453","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299885-elevated-creatine-kinase-ck-and-myositis-triggered-by-immune-checkpoint-inhibitors-muscle-mysteries-unveiled","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:07:59Z","timestamp":1729224479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299885-elevated-creatine-kinase-ck-and-myositis-triggered-by-immune-checkpoint-inhibitors-muscle-mysteries-unveiled"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.71742","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}